{
    "clinical_study": {
        "@rank": "116148", 
        "arm_group": [
            {
                "arm_group_label": "Study group", 
                "arm_group_type": "Experimental", 
                "description": "Application of Dexmedetomidine (Dexdor\u00ae) perioperatively for a maximum of 48 hours\nDosing Scheme:\nduring operation and mechanical ventilation: 0,7\u03bcg/kgABW/h; recovery time until extubation: 0,4\u03bcg/kgABW/h; after extubation: 0,2-1,4\u03bcg/kgABW/h"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Application of placebo for a maximum of 48 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "The drug Dexmedetomidine will be investigated in patients (men and women) undergoing\n      elective cardiac or pancreatic surgery. The study medication will be administered\n      perioperatively by intravenous infusion continuously (at the longest 48 h) to prevent/reduce\n      the rate of Delirium and the incidence of Postoperative cognitive deficit (POCD)."
        }, 
        "brief_title": "Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Pancreatic Surgery (Neuprodex)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Delirium", 
            "Postoperative Cognitive Deficit (POCD)"
        ], 
        "condition_browse": {
            "mesh_term": "Delirium"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients aged \u2265 60 years\n\n          2. Male and female patients undergoing elective cardiac or pancreatic surgery of both\n             Campus Charit\u00e9 Mitte and Campus Virchow - Klinikum, Charit\u00e9 - Universit\u00e4tsmedizin\n             Berlin\n\n          3. Offered patient information and written consent by the patient (according to German\n             Drug Law \u00a7 40 (1) 3b)\n\n          4. Premedication only with benzodiazepines\n\n          5. Pain therapy during the operation with regional procedures and/or Sufentanil/Fentanyl\n\n          6. Anesthesia in cardio surgery according to Heart-Lung-Apparatus\n\n          7. Anesthesia with hypnotic agent Propofol\n\n          8. Pain therapy after operation according to S3-Guideline\n\n          9. Postoperative medication for anxiolysis only with benzodiazepines\n\n        Exclusion Criteria:\n\n          1. Known drug intolerance/allergy: dexmedetomidine or to other ingredients\n\n          2. Lacking willingness to save and hand out pseudonymised data within the clinical trial\n\n          3. Accommodation in an institution due to an official or judicial order (according to\n             AMG \u00a740 (1) 4)\n\n          4. Employee of the Charit\u00e9 - Universit\u00e4tsmedizin Berlin CVK/CCM\n\n          5. Illiteracy\n\n          6. Inability to speak and/or read German\n\n          7. Minimal mental status examination (MMSE) < 24\n\n          8. Severe hearing loss or visual impairment\n\n          9. Acute brain injury\n\n         10. Intracranial haemorrhage within one year before participation in the study\n\n         11. Manifest psychiatric disease\n\n         12. Known illicit substance abuse\n\n         13. Acute intoxication\n\n         14. For women: Pregnancy or positive pregnancy test within the preoperative screening\n\n         15. Homeless or other circumstances, where the patient would not be reachable by\n             telephone or postal services for the 3-months follow up\n\n         16. Participation in another interventional clinical trial according to the German Drug\n             Law at time of inclusion and during the trial\n\n         17. Acute circulatory failure at time of randomisation (severe hypotension with mean\n             arterial pressure < 55 mmHg despite vasopressors or optimal preload)\n\n         18. AV-conduction-block II or III (unless pacemaker installed)\n\n         19. Severe bradycardia (heart-rate < 50 bpm, preoperative, permanent)\n\n         20. Spinal cord injury with known autonomic dysregulation\n\n         21. Preoperative acute cerebrovascular event with neurologic residues\n\n         22. Liver insufficiency (Child C cirrhosis, MELD Score > 17)\n\n         23. Application of Remifentanil during the operation\n\n         24. Deep sedation (RASS, -4 to -5)\n\n         25. Administration of Clonidine during administration of the study drug\n\n         26. Additional administration of Dexmedetomidine within 3 months after study inclusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096068", 
            "org_study_id": "Neuprodex"
        }, 
        "intervention": [
            {
                "arm_group_label": "Study group", 
                "description": "Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)", 
                "intervention_name": "Dexmedetomidine (Dexdor\u00ae)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control group", 
                "description": "Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.", 
                "intervention_name": "0.9% Sodium Chloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dexmedetomidine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Neuroprotection", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "claudia.spies@charite.de", 
                "last_name": "Claudia Spies, MD, Prof.", 
                "phone": "+49 30 450 551102"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "13353"
                }, 
                "name": "Department of Anesthesiology and Intensive Care Medicine, Campus Charit\u00e9 Mitte and Campus Virchow - Klinikum, Charit\u00e9- Universit\u00e4tsmedizin"
            }, 
            "investigator": [
                {
                    "last_name": "Claudia Spies, MD, Prof.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Anika M\u00fcller, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Pancreatic Surgery (NEUPRODEX)", 
        "overall_contact": {
            "email": "claudia.spies@charite.de", 
            "last_name": "Claudia Spies, MD, Prof.", 
            "phone": "+49 30 450 551102"
        }, 
        "overall_official": {
            "affiliation": "Charit\u00e9 - University Medicine, Berlin, Germany", 
            "last_name": "Claudia Spies, MD, Prof.", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of postoperative delirium measured with the Confusion Assessment Method for the ICU (CAM-ICU) or the Confusion Assessment Method (CAM)", 
            "measure": "Incidence of postoperative delirium", 
            "safety_issue": "No", 
            "time_frame": "Until the 7th postoperative day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096068"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Charite University, Berlin, Germany", 
            "investigator_full_name": "Claudia Spies", 
            "investigator_title": "Department of Anesthesiology and Intensive Care Medicine CVK/CCM", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Incidence of Subsyndromal Delirium (SSD) and postoperative Delirium measured with the  Intensive Care Delirium Screening Checklist (ICDSC)", 
                "measure": "Incidence of subsyndromal delirium and postoperative delirium", 
                "safety_issue": "No", 
                "time_frame": "Until the 7th postoperative day"
            }, 
            {
                "description": "Duration of intensive care unit-delirium  measured with the Confusion Assessment Method for the ICU (CAM-ICU) and the Intensive Care Delirium Screening Checklist (ICDSC)", 
                "measure": "Duration of delirium in the intensive care unit", 
                "safety_issue": "No", 
                "time_frame": "Until the 7th postoperative day"
            }, 
            {
                "description": "Severity of Delirium measured with the Delirium Rating Scale (DRS)", 
                "measure": "Severity of Delirium", 
                "safety_issue": "No", 
                "time_frame": "Until the 7th postoperative day"
            }, 
            {
                "description": "Severity of anxiety measured with the Faces Anxiety Scale (FAS)", 
                "measure": "Severity of anxiety", 
                "safety_issue": "No", 
                "time_frame": "Up to three months"
            }, 
            {
                "description": "Management of sedation measured by the Richmond Agitation Sedation Scale (RASS)", 
                "measure": "Management of sedation", 
                "safety_issue": "No", 
                "time_frame": "Until the 7th postoperative day"
            }, 
            {
                "description": "Management of Vigilance measured by Glasgow Coma Scale (GCS)", 
                "measure": "Management of vigilance", 
                "safety_issue": "No", 
                "time_frame": "Until the 7th postoperative day"
            }, 
            {
                "description": "Management of analgesia and pain levels measured by Numeric Rating Scale - Visualized (NRS-V), the Faces Pain Scale - Revised (FPS-R), the Behavioral Pain Scale (BPS) or the Behavioral Pain Scale for Non-Intubated (BPS-NI)", 
                "measure": "Management of analgesia and pain levels", 
                "safety_issue": "No", 
                "time_frame": "Up to three months"
            }, 
            {
                "measure": "Relevant medication", 
                "safety_issue": "No", 
                "time_frame": "Until the 7th postoperative day"
            }, 
            {
                "description": "Severity of illness measured by Sequential Organ Failure Assessment (SOFA-Score), Simplified Acute Physiology Score (SAPS II) and the Therapeutic Intervention Scoring System (TISS-28)", 
                "measure": "Severity of illness", 
                "safety_issue": "No", 
                "time_frame": "Until the 7th postoperative day"
            }, 
            {
                "measure": "Mechanical ventilation/weaning failure", 
                "safety_issue": "No", 
                "time_frame": "Until the 7th postoperative day"
            }, 
            {
                "measure": "Intraoperative cerebral oxymetry", 
                "safety_issue": "No", 
                "time_frame": "At time of surgery"
            }, 
            {
                "description": "Depth of consciousness index measured by processive Electroencephalography and Electromyography (EEG/EMG) -Data (SedLine\u00ae)", 
                "measure": "Depth of consciousness index", 
                "safety_issue": "No", 
                "time_frame": "At time of surgery"
            }, 
            {
                "description": "Complete blood count performance (Sysmex\u00ae) and acetylcholinesterase-analysis", 
                "measure": "Determination of blood levels", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline complete blood count performance (Sysmex\u00ae) and acetylcholinesterase-analysis at third postoperative day"
            }, 
            {
                "measure": "Cortisol-analysis", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline cortisol-analysis at third postoperative day"
            }, 
            {
                "measure": "Organ dysfunctions", 
                "safety_issue": "No", 
                "time_frame": "Up to three months"
            }, 
            {
                "description": "Infections according to surgical site infections (SSI) and according to the US Centers for Disease Control and Preventions (CDC).", 
                "measure": "Infections", 
                "safety_issue": "No", 
                "time_frame": "Up to three months"
            }, 
            {
                "measure": "ICU length of stay", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of intensive care stay, an expected average of 2 days"
            }, 
            {
                "description": "Discharge criteria have to be met according to Post Anaesthetic Discharge Scoring System (PADSS) for monitoring patients discharge.", 
                "measure": "Hospital length of stay", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 2 weeks"
            }, 
            {
                "description": "Quality of life is measured by EQ-5D (EuroQol Group), a measure generating a single index value for health status with considerable potential for use in health care evaluation", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Up to three months"
            }, 
            {
                "description": "Incidence of postoperative cognitive dysfunction (POCD) is measured by  Cambridge Neuropsychological Test Automated Battery (CANTAB\u00ae) and Mini Mental State Examination (MMSE)", 
                "measure": "Incidence of postoperative cognitive dysfunction", 
                "safety_issue": "No", 
                "time_frame": "Up to three months"
            }, 
            {
                "measure": "Mortality", 
                "safety_issue": "No", 
                "time_frame": "Up to three months"
            }
        ], 
        "source": "Charite University, Berlin, Germany", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Claudia Spies", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}